About · OncAdios LLC
Jesús Gómez-Navarro, M.D.
A senior oncology drug development consultant and board-certified medical oncologist with 30+ years turning oncology science into development programs approved by regulators worldwide, the FDA, EMA, PMDA, and NMPA among them — now the independent advisory practice behind OncAdios.
Jesús Gómez-Navarro is a board-certified medical oncologist with more than three decades in oncology drug development. As Immuno-oncology Clinical Lead, Pfizer Oncology, he contributed to advancing the anti-CTLA-4 antibody tremelimumab from first-in-human through Phase 3 (later approved as IMJUDO). He went on to oncology drug-development roles at Millennium Pharmaceuticals in Cambridge, Massachusetts. As VP, Head of Clinical R&D at Takeda Oncology (2011–2020) and Takeda's inaugural Distinguished R&D Fellow (2020–2022), he oversaw seven anticancer approvals worldwide, including by the FDA, EMA, PMDA, and NMPA.
He founded OncAdios LLC in 2022 to bring that judgment to AI-oncology and biotech companies as a fractional CMO, board director or scientific advisor — the seat that carries a program through its endpoint, indication, trial-design, and FDA decisions. He is its sole principal; the practice has no partners, associates, or other named principals. Based in Madrid; much of the career above was built in the Boston and Cambridge oncology cluster, and he travels there when an engagement warrants it.
Career
Three decades in oncology drug development, then an independent practice.
Early career
Pfizer
Oncology drug development
Mid career
Millennium Pharmaceuticals
Oncology drug development
Cambridge, MA
2011 – 2022
Takeda Oncology
VP, Head of Clinical R&D (2011–2020)
Distinguished R&D Fellow (2020–2022)
Cambridge, MA
2022 – present
OncAdios LLC
Founder · Fractional CMO · Board director · Scientific advisor
Approvals contributed to across the career arc
NINLARO · ADCETRIS · ALUNBRIG · ICLUSIG · ZEJULA · CABOMETYX · EXKIVITY · and tremelimumab (later approved as IMJUDO) advanced from first-in-human through Phase 3.
What He Advises On
The decisions that determine whether an oncology molecule reaches the next phase.
- Endpoint and indication strategy the FDA can actually review — translating AI-discovered targets and prioritized candidates into endpoint structures, trial designs, and pre-IND positions the agency has precedent to accept, and knowing when the science warrants a reasoned departure the evidence can defend.
- Trial designs that enroll — pressure-testing inclusion/exclusion logic, referral patterns, line-of-therapy windows, and combination practicality against what community oncologists will actually prescribe, before the protocol is locked.
- Regulatory translation — putting the science into the language and documentation tier a CDER review division will accept.
- Independent adjudication for boards and investors — an independent read on whether a third party's oncology development story is calibrated, before a round, a partnership, or a disciplined no.
The entry point is a fixed-scope Calibration Sprint, with a development-path track and a first-in-human evidence track; ongoing work is a fractional CMO role or a board or scientific-advisor seat. The through-line is a single senior operator who stays accountable for the decision. How the consulting works →
Scientific & Professional Record
The verifiable record.
OncAdios is a public credibility and verification surface. The identity and scientific record above can be verified directly at the independent sources below — the authoritative places to find the peer-reviewed publication and presentation history.
- NCBI My Bibliography — the complete author-curated publication record, hosted by the U.S. National Library of Medicine: ncbi.nlm.nih.gov/myncbi/…
- ORCID — the authoritative scholarly identifier: orcid.org/0000-0003-2787-0842
- LinkedIn — professional history and current activity: linkedin.com/in/jesus-gomez-navarro
- ResearchGate — research profile and selected publications: researchgate.net/profile/Jesus-Gomez-Navarro
- Selected publications — peer-reviewed work on CTLA-4 blockade and the tremelimumab program, and earlier adenoviral gene-therapy research, each entry linked to its PubMed record.
Board-certified medical oncologist · 30+ years in oncology drug development · Contributions to anticancer approvals worldwide, including by the FDA, EMA, PMDA, and NMPA.
Start a Conversation
A small number of engagements per year.
If the decision in front of your program in the next 90 to 180 days is real and the program turns on it, the conversation is worth having. The fixed-scope Calibration Sprint is the front door.